This week in Rheumatology

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Rheumatology. This week we're covering 10 notable papers spanning the fibrosing diseases from skin to kidney, lupus treatment response, and the infection and mortality burden that shadows our immunomodulatory therapies, with a stop in crystal and iron-related joint disease. Let's dive in.

We start with scleroderma, where three papers move from early mechanism to decade-long outcomes. In Annals of the Rheumatic Diseases, Eming and colleagues report a randomised, placebo-controlled phase 2 proof-of-concept trial of dupilumab, which blocks the interleukin 4 receptor alpha, in localised scleroderma [1]. After six months, treated patients showed significant clinical improvement over placebo, along with reduced local inflammation, suppression of the interleukin 4 and 13 gene signature, and partial suppression of genes encoding fibrosis-inducing proteins. The abstract gives no effect sizes, and this is a short, early-phase study, so it establishes a mechanistic rationale rather than a treatment standard; the authors frame it as a signal for other fibrosing diseases, systemic sclerosis included. At the other end of the therapeutic spectrum, Henes and colleagues in Lancet Rheumatology followed 80 patients from the prospective European NISSC1 cohort for a median of just over nine years after autologous stem-cell transplantation for severe progressive systemic sclerosis [2]. Progression-free survival was about 60 percent at ten years, and 43 percent of patients stayed in remission without any immunosuppression across the decade. The costs are real: five patients died of transplant-related causes, and late malignancy and serious infection each accounted for further deaths. As the authors note, this real-world dataset now becomes the benchmark against which CAR T-cell and other cellular therapies will be judged. Then, in Seminars in Arthritis and Rheumatism, Chan and colleagues describe 97 new cases of scleroderma renal crisis from an international inception survey [3]. Nearly all patients received an ACE inhibitor, but more than half of patients needed three or more antihypertensives, almost half of patients required dialysis, and one-year mortality remained high. The intriguing finding is that survival was best when blood pressure was controlled over five to ten days rather than within the expert-recommended 72 hours. This is observational, with modest numbers and potential confounding by severity, so it reopens the question of how quickly to lower pressure rather than settling it.

Turning to lupus, two papers look at who responds to escalation and to what. Dyball and colleagues, in Lancet Rheumatology, analysed 422 patients with moderate-to-severe lupus in the British Isles Lupus Assessment Group Biologics Register who started rituximab, belimumab or standard immunosuppression [4]. Fewer than a quarter of patients reached major clinical response at twelve months. Black patients arrived with higher disease activity, more damage and more comorbidity, and only about one in ten Black patients responded, compared with roughly a quarter of White patients; after adjustment, their odds of response remained substantially lower. Subgroups were small, particularly for East Asian patients, but the authors argue the data support more personalised and equitable approaches and greater diversity in trials. Meanwhile, in Lupus Science and Medicine, Pike and colleagues present a post hoc analysis of the phase 2 PAISLEY study of deucravacitinib, an oral tyrosine kinase 2 inhibitor [5]. Among patients with at least six involved joints, about 60 percent on the 3 milligram twice-daily dose had complete resolution of active joints at week 48, against about 31 percent on placebo, with supportive findings on half-reduction of joint counts and on the musculoskeletal domains of both disease activity indices. Higher doses produced smaller responses, and this is exploratory, so phase 3 data will determine whether arthritis becomes a distinct selling point for the drug.

Our third theme is infection and mortality, the recurring cost of the immune suppression our patients carry. In Rheumatology, Kwok and colleagues used MarketScan claims from 2016 to 2023 covering more than 270,000 people starting advanced therapies across immune-mediated diseases [6]. About one in seven of these patients had at least a month of overlapping exposure to two different biologic or targeted synthetic classes, often involving a TNF inhibitor and most commonly in the spondyloarthritis family. These combination episodes were typically brief, with a median of about six weeks, yet they carried roughly 60 percent higher risk of serious infection than monotherapy, with variation by regimen and by disease; axial spondyloarthritis was the exception. Claims data cannot fully separate deliberate combination from switching overlap, but the signal argues for caution as dual targeting gains attention. Also in Rheumatology, Rutter and colleagues used whole-population English hospital data to track mortality in rare autoimmune rheumatic diseases from 2013 to 2020 [7]. Mortality remained more than twice that of the general population despite a modest decline, with infection deaths roughly fourfold higher and cardiovascular and respiratory deaths also clearly elevated. Systemic sclerosis, the inflammatory myopathies and microscopic polyangiitis carried the highest mortality, while opportunistic infections were rarely the recorded cause, pointing to common infections and cardiovascular risk as the preventable targets. Looking ahead, Winthrop and colleagues in Annals of the Rheumatic Diseases offer a practical revaccination framework for adults with autoimmune disease treated with BCMA-targeted immune-reset therapies, including CAR T cells and bispecific engagers [8]. The available evidence shows these agents lower vaccine-specific antibody titres and total immunoglobulins. Because much of the data are borrowed from oncology, where treatment exposure differs, the authors present a pragmatic approach with minimal serologic monitoring that is explicitly provisional.

Finally, two papers on metabolic and crystal-adjacent joint disease. In Arthritis and Rheumatology, Gao and colleagues randomised 280 men with gout at a single Chinese centre to a smartphone-enabled treat-to-target model, combining automated reminders, tiered education, remote urate monitoring and weekly physician review, or to usual care [9]. At twelve months, 85 percent of patients in the digital arm reached a serum urate below 360 micromoles per litre, compared with just under half of patients in usual care. Flares were less frequent, adherence was higher, and exploratory metabolic markers including glucose, HbA1c and LDL cholesterol also improved, with similar adverse event rates. The trial was open-label, single-centre and enrolled only men, and the authors call for multicentre studies on generalisability and cost-effectiveness. In Annals of the Rheumatic Diseases, Kiely and colleagues examined 373 participants from EULAR inception cohorts to ask whether HFE genotypes cause arthropathy independent of iron overload [10]. About 43 percent of carriers of other HFE genotypes, including H63D variants, met haemochromatosis arthropathy classification criteria, compared with about 7 percent of osteoarthritis and calcium pyrophosphate controls, and neither ferritin nor transferrin saturation predicted fulfilment. The authors propose a new entity, HFE-associated arthropathy without genetic haemochromatosis, characterised by metacarpophalangeal or ankle disease. Selection of referred patients with unexplained joint pain inflates prevalence, so this is a classification proposal awaiting population-level confirmation.

If you only have time for one paper this week, make it the smartphone-enabled gout trial from Gao and colleagues in Arthritis and Rheumatology [9]. It offers randomised evidence that the long-standing gap between urate targets and real-world attainment can be narrowed substantially with a scalable care model, while leaving open whether the effect transfers beyond a single centre.

That's your roundup for This Week in Rheumatology. The full transcript and references are available on the episode page. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.